Font Size




Menu Style

AVG Home


AVG Webinar Series

AVG Webinar series

You can listen to the recordings from the AVG webinars which have taken place to date via the links below:

25 October 2022: Treatments/Antiviral Therapeutics - link to the recording

24 January 2023: Antiviral Resistance - link to the recording

20 June 2023: The Present and Future of Treatment Oriented Surveillance - link to the recording

30 Oct 2023: Challenges and Promise of Clinical Trials for Respiratory Antivirals - link to the recording

Details of dates and topics for 2024 will be posted soon – watch this space!


7th AVG Conference (in-person)

We’ve had some great feedback…. adobe pdf icon2

SARS-CoV-2 / COVID-19   
Antiviral News

AVG Overview

The isirv Antiviral Group (isirv-AVG) was established as a special interest group of isirv at the time of merger in April 2011 of the former Neuraminidase Inhibitor Susceptibility Network (NISN) with isirv. Its specific objectives are to promote understanding of the clinical use of antivirals against respiratory viruses, collate and provide up to date information on the emergence of antiviral resistance, and communicate expert commentary on preclinical and clinical development of potential novel/new antivirals. Read More


   isirv Antiviral Group (isirv-AVG) 10th Anniversary

The isirv Antiviral Group was established in 2011 following the merger of the Neuraminidase Inhibitor Susceptibility Network (NISN) with the International Society for Influenza and Other Respiratory Virus Diseases (isirv). Read more

To fulfil its objectives of promoting understanding of the development and clinical use of antivirals against respiratory viruses and the emergence of resistance, the Group has organised a series of AVG conferences on specific topics in different geographical locations plus other smaller specialist meetings and workshops.

The Group gratefully acknowledges the contribution of its partners and the generous financial support from many privateand public organisations that have ensured the success of the Group’s programme of events over the past 10 years.

 Recent AVG Events

Therapeutics for COVID-19, a special virtual conference, 6-8 October 2020
The 3-day programme addressed the latest advances in the development of antivirals and other therapeutics for use against COVID-19 and possibilities for improved clinical management. Oral and e-poster presentations are available. Read more
AVG Polymerase Inhibitor Resistance Meeting, at the Offices of the Task Force for Global Health, Atlanta, USA, 7-8 August 2019
The participants at this small specialist meeting, including public health, academic and corporate representatives who are conducting studies on the new antivirals targeting the influenza RNA polymerase, met to discuss the impact of resistance to these inhibitors. A report of the meeting is incorporated in an Assessment of the Current State of the Art report published in Antiviral Research and now on the AVR journal web site as a highlighted article. Read more

Antiviral News


Antiviral Susceptibility of Highly Pathogenic Avian Influenza A(H5N1) Viruses Circulating Globally in 2022-2023...  read more

A community cluster of influenza A(H3N2) virus infection with reduced susceptibility to baloxavir due to a PA E199G substitution in Japan, February to March 2023...  read more

Safety and Efficacy of Baloxavir Marboxil in Influenza-infected Children 5-11 Years of Age: A Post Hoc Analysis of a Phase 3 Study (miniSTONE-2)...  read more

The combined effect of oseltamivir and favipiravir on influenza A virus evolution in patients hospitalized with severe influenza...  read more

Endonuclease and other Polymerase Inhibitors
In Vivo Antiviral Activity of Baloxavir against PA/I38T-Substituted Influenza A Viruses at Clinically Relevant Doses... read more
New Drug Discovery
Rational design and optimization of acylthioureas as novel potent influenza virus non-nucleoside polymerase inhibitors... read more
Clinical Trials & Case Studies
Multicenter, randomized controlled, open label evaluation of the efficacy and safety of arbidol hydrochloride tablets in the treatment of influenza-like cases... read more
Advanced virtual screening enables the discovery of a host-targeting and broad-spectrum antiviral more
Antiviral News prepared by: Dr Jeremy C. Jones, Department of Infectious Diseases, St Jude Children’s Research Hospital, Memphis, TN, USA
Visit us on:  facebook  twitter